Covaxin finds place in Oman's list of approved Covid-19 vaccines

Bharat Biotech tweeted, "Covaxin has now been added to the approved list of Covid-19 vaccines for travel to Oman without quarantine. This will facilitate travelers from India vaccinated with Covaxin."

Bharat Biotech, Covaxin
Bharat Biotech's Covaxin
Press Trust of India New Delhi
2 min read Last Updated : Oct 28 2021 | 1:16 PM IST

Bharat Biotech's Covaxin has been included to the approved list of Covid-19 vaccines for travel to Oman without quarantine.

In a tweet, Bharat Biotech noted: "Covaxin has now been added to the approved list of #COVID19 vaccines for travel to Oman without quarantine. This will facilitate travelers from India vaccinated with Covaxin."

The vaccine major cited a press release issued by the Embassy of India, Muscat, in this regard.

"Embassy of India, Muscat, is pleased to inform that the Government of the Sultanate of Oman has added Covaxin to the approved list of COVID-19 vaccines for travel to Oman. The Civil Aviation Authority issued a notification on 27 October regarding this," the release stated.

All passengers from India who have received two doses of Covaxin at-least 14 days before the estimated arrival date will now be able to travel to Oman without the requirement of quarantine, it added.

All other COVID-19 related requirements/conditions, such as pre-arrival RT-PCR test shall be applicable for such passengers, the release stated.

This notification will significantly ease travel to Oman for Indian nationals who have taken Covaxin, it noted.

Passengers who have taken AstraZeneca/Covishield are already permitted to travel to Oman without quarantine.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBharat BiotechCoronavirus Vaccine

First Published: Oct 28 2021 | 12:53 PM IST

Next Story